Cell Point (India)NSE:CELLPOINT -5.36%73 EBITDA Margin % is 3.30% as of Mar. 2026, which is 4% below its 10-year median of 3.43. GuruFocus rates NSE:CELLPOINT with a GF Score™ of 73/100 and a GF Value™ of ₹34.72 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,128 Retail - Cyclical companies, Cell Point (India) ranks worse than 71.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cell Point (India)'s EBITDA for the
six
months ended in Mar. 2026 was ₹63 Mil. Cell Point (India)'s Revenue for the
six
months ended in Mar. 2026 was ₹1,910 Mil. Therefore, Cell Point (India)'s EBITDA margin for the quarter that ended in Mar. 2026 was 3.30%.
Cell Point (India) (NSE:CELLPOINT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cell Point (India) EBITDA Margin % Related Terms
Cell Point (India) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cell Point (India)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CELLPOINT vs CASY, WSM, ULTA: EBITDA Margin % Comparison
For the Specialty Retail subindustry, Cell Point (India)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Point (India) EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Cell Point (India)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cell Point (India)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Point (India) (NSE:CELLPOINT) has a EBITDA Margin % of 3.30% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cell Point (India) and its competitors. This is near median its historical median of 3.43. Over the past decade, Cell Point (India)'s EBITDA Margin % has ranged from 2.94 to 6.28. According to the industry distribution chart, Cell Point (India) ranks #810 out of 1128 companies in the Retail - Cyclical industry, placing it in the top 71.8%.
Is Cell Point (India)'s EBITDA Margin % too high?
Cell Point (India)'s current EBITDA Margin % of 3.30% is near median its 10-year median of 3.43. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 6.28. The Retail - Cyclical industry median EBITDA Margin % is 7.48. Cell Point (India)'s value of 3.30% is 55.9% below this industry median. Based on the distribution chart, Cell Point (India) ranks #810 out of 1128 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, Cell Point (India) has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cell Point (India)'s EBITDA Margin % compare to CASY and WSM?
According to the Retail - Cyclical industry distribution chart, Cell Point (India) ranks #810 out of 1128 companies for EBITDA Margin %. This places Cell Point (India) in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Cell Point (India)'s value of 3.30% is 55.9% below this benchmark. Historically, Cell Point (India)'s own EBITDA Margin % has ranged from 2.94 to 6.28 over the past decade. While the company's 10-year median is 3.43 vs. the industry median of 7.48, Cell Point (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.48, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cell Point (India)'s current EBITDA Margin % of 3.30% is 55.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cell Point (India) and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Point (India)'s current EBITDA Margin % is 3.30%, which is near median its own 10-year median of 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Point (India) stock overvalued right now?
Based on GuruFocus' analysis, Cell Point (India) (NSE:CELLPOINT) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹34.72, compared to a current price of ₹15.00 — trading 56.8% below its estimated fair value. The current EBITDA Margin % is 3.30%, which is near median its 10-year median of 3.43 and 55.9% below the Retail - Cyclical industry median of 7.48. Cell Point (India)'s overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cell Point (India) (NSE:CELLPOINT), the current EBITDA Margin % is 3.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cell Point (India) (NSE:CELLPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Cell Point (India) stock appears to be undervalued.
The current stock price of ₹15.00 is trading 56.8% below its estimated GF Value™ of ₹34.72.
GuruFocus considers Cell Point (India) to be Significantly Undervalued.
Key valuation signals for NSE:CELLPOINT:
EBITDA Margin %: 3.30% (near median its 10-year median of 3.43)
GF Value™: ₹34.72 vs. price of ₹15.00 (56.8% below fair value)
Industry Position: 55.9% below the Retail - Cyclical median (#810 of 1128)
No single metric tells the full story. See the NSE:CELLPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cell Point (India) Ltd is engaged in multi-brand retail selling of smartphones, tablets, mobile accessories, and mobile-related products of various brands such as Apple, Samsung, Oppo, Realme, Nokia, Vivo, Xiaomi, Nokia, Redmi, Techno, One Plus, etc. It is also engaged in retail selling of consumer durable electronics goods, smart televisions, smart watches, and air conditioners of various brands such as Xiaomi, Realme, and One Plus among others. The company operates in a single segment and derives revenue from its operations in India.
73GF Score
Get the complete analysis for NSE:CELLPOINT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CELLPOINT has been successfully added to your 
